Esperion Therapeutics, Inc.
Simbolis: ESPR
NASDAQ
2.05
USDRinkos kaina šiandien
-0.9875
P/E santykis
0.0209
PEG koeficientas
349.36M
MRK kapitalizacija
- 0.00%
DIV pajamingumas
Esperion Therapeutics, Inc. (ESPR) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2002 | 2001 | 2000 | 1999 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 497.89 | 82.2 | 124.8 | 208.9 | |||||||||||||||||
balance-sheet.row.short-term-investments | 17.43 | 0 | 42.1 | 50.4 | |||||||||||||||||
balance-sheet.row.net-receivables | 168.33 | 48.5 | 33.7 | 22.9 | |||||||||||||||||
balance-sheet.row.inventory | 202.09 | 65.6 | 35.2 | 34.4 | |||||||||||||||||
balance-sheet.row.other-current-assets | 20.89 | 4.7 | 9.9 | 62.8 | |||||||||||||||||
balance-sheet.row.total-current-assets | 902.02 | 201.1 | 246.7 | 329 | |||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 11.3 | 4.7 | 1.2 | 2.6 | |||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.intangible-assets | 0.22 | 0.1 | 0.1 | 0.1 | |||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0.22 | 0.1 | 0.1 | 0.1 | |||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 42.1 | 50.4 | |||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | -50.4 | |||||||||||||||||
balance-sheet.row.other-non-current-assets | -3.72 | 0 | -42.1 | 50 | |||||||||||||||||
balance-sheet.row.total-non-current-assets | 11.52 | 4.7 | 1.3 | 52.6 | |||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-assets | 913.55 | 205.8 | 247.9 | 381.6 | |||||||||||||||||
balance-sheet.row.account-payables | 99.56 | 31.7 | 23 | 17.6 | |||||||||||||||||
balance-sheet.row.short-term-debt | 38.29 | 36.4 | 0.4 | 1.4 | |||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.long-term-debt-total | 1288.3 | 501.5 | 260.6 | 258.8 | |||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0.6 | |||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||||
balance-sheet.row.other-current-liab | 285.83 | 62.7 | 65.4 | 48.7 | |||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 1983.59 | 504.6 | 479.4 | 505.2 | |||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.capital-lease-obligations | 9.46 | 3 | 1 | 1.9 | |||||||||||||||||
balance-sheet.row.total-liab | 2480.18 | 660.8 | 571.7 | 578.5 | |||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.common-stock | 0.42 | 0.1 | 0.1 | 0.1 | |||||||||||||||||
balance-sheet.row.retained-earnings | -5895.67 | -1549.3 | -1340 | -1106.4 | |||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 3256.52 | 1094.2 | -0.1 | 0 | |||||||||||||||||
balance-sheet.row.total-stockholders-equity | -2638.73 | -455 | -1340 | -1106.4 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | -158.55 | 205.8 | -768.3 | -527.8 | |||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-equity | -2638.73 | -455 | -1340 | -1106.4 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | -158.55 | - | - | - | |||||||||||||||||
Total Investments | 17.43 | 0 | 84.2 | 100.9 | |||||||||||||||||
balance-sheet.row.total-debt | 1329.61 | 540.9 | 260.9 | 260.2 | |||||||||||||||||
balance-sheet.row.net-debt | 849.15 | 458.7 | 136.2 | 51.3 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2002 | 2001 | 2000 | 1999 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -209.25 | -209.2 | -233.7 | -269.1 | |||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0.16 | 0.2 | 0.5 | 0.6 | |||||||||||||||||
cash-flows.row.deferred-income-tax | -17.56 | 36.5 | 0 | -2.6 | |||||||||||||||||
cash-flows.row.stock-based-compensation | 11.96 | 12 | 15.2 | 24.3 | |||||||||||||||||
cash-flows.row.change-in-working-capital | 13.68 | 13.7 | -3.4 | -52.5 | |||||||||||||||||
cash-flows.row.account-receivables | -14.77 | -14.8 | -10.8 | -10.5 | |||||||||||||||||
cash-flows.row.inventory | -30.42 | -30.4 | -0.8 | -18.3 | |||||||||||||||||
cash-flows.row.account-payables | 8.68 | 8.7 | 5.6 | -34.1 | |||||||||||||||||
cash-flows.row.other-working-capital | 50.18 | 50.2 | 2.6 | 10.4 | |||||||||||||||||
cash-flows.row.other-non-cash-items | 65.52 | 11.5 | 46.5 | 35.5 | |||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -135.49 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | -59.9 | -50.5 | |||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 42.5 | 42.5 | 68 | 0 | |||||||||||||||||
cash-flows.row.other-investing-activites | 42.5 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 42.5 | 42.5 | 8.1 | -50.5 | |||||||||||||||||
cash-flows.row.debt-repayment | -15.51 | -15.5 | -58.2 | -0.8 | |||||||||||||||||
cash-flows.row.common-stock-issued | 13.52 | 66 | 90.8 | 218.7 | |||||||||||||||||
cash-flows.row.common-stock-repurchased | -0.02 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.other-financing-activites | 53.81 | 0 | -50.2 | 50.3 | |||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 50.46 | 50.5 | 32.6 | 268.2 | |||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.net-change-in-cash | -42.53 | -42.5 | -134.1 | -46.1 | |||||||||||||||||
cash-flows.row.cash-at-end-of-period | 480.46 | 82.2 | 124.8 | 258.9 | |||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 522.99 | 124.8 | 258.9 | 305 | |||||||||||||||||
cash-flows.row.operating-cash-flow | -135.49 | -135.5 | -174.8 | -263.8 | |||||||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.free-cash-flow | -135.49 | -135.5 | -174.8 | -263.8 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2002 | 2001 | 2000 | 1999 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 116.33 | 116.3 | 75.5 | 78.4 | |||||||||||||||||
income-statement-row.row.cost-of-revenue | 43.27 | 43.4 | 27 | 14.2 | |||||||||||||||||
income-statement-row.row.gross-profit | 73.06 | 72.9 | 48.5 | 64.2 | |||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.research-development | 86.11 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-general-administrative | 29.82 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 15.6 | - | - | - | |||||||||||||||||
income-statement-row.row.other-expenses | 22.52 | 5.3 | 2.7 | 4 | |||||||||||||||||
income-statement-row.row.operating-expenses | 248.79 | 228.5 | 228 | 291 | |||||||||||||||||
income-statement-row.row.cost-and-expenses | 271.9 | 271.9 | 255 | 305.2 | |||||||||||||||||
income-statement-row.row.interest-income | 5.11 | 4.8 | 2.6 | 0.1 | |||||||||||||||||
income-statement-row.row.interest-expense | -0.09 | 59 | 56.8 | 46.4 | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 15.6 | - | - | - | |||||||||||||||||
income-statement-row.row.total-other-income-expensenet | -53.69 | -53.7 | -54.2 | -42.4 | |||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-operating-expenses | 22.52 | 5.3 | 2.7 | 4 | |||||||||||||||||
income-statement-row.row.total-operating-expenses | -53.69 | -53.7 | -54.2 | -42.4 | |||||||||||||||||
income-statement-row.row.interest-expense | -0.09 | 59 | 56.8 | 46.4 | |||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 1.36 | 0.2 | 2.7 | 4 | |||||||||||||||||
income-statement-row.row.ebitda-caps | -154.28 | - | - | - | |||||||||||||||||
income-statement-row.row.operating-income | -155.56 | -155.6 | -179.5 | -226.7 | |||||||||||||||||
income-statement-row.row.income-before-tax | -209.25 | -209.2 | -233.7 | -269.1 | |||||||||||||||||
income-statement-row.row.income-tax-expense | 27.42 | 0 | 54.2 | 49.7 | |||||||||||||||||
income-statement-row.row.net-income | -236.75 | -209.2 | -287.8 | -318.8 |
Dažnai užduodami klausimai
Kas yra Esperion Therapeutics, Inc. (ESPR) bendras turtas?
Esperion Therapeutics, Inc. (ESPR) bendras turtas yra 205796000.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra 66219000.000.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.628.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra -1.205.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra -2.035.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra -1.337.
Kas yra Esperion Therapeutics, Inc. (ESPR) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra -209248000.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 540947000.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 228466000.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 82248000.000.